Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

[A case of non-acquired immunodeficiency syndrome-defining lung adenocarcinoma in a multidrug-resistant human immunodeficiency virus-positive patient].

Mori N, Maeda H, Fujiwara K, Taniguchi H.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1381-3. Japanese.

PMID:
24196075
2.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chêne G; ANRS 139 TRIO Trial Group.

Clin Infect Dis. 2009 Nov 1;49(9):1441-9. doi: 10.1086/630210.

PMID:
19814627
3.

Lung cancer in patients with immunodeficiency syndrome.

Karp J, Profeta G, Marantz PR, Karpel JP.

Chest. 1993 Feb;103(2):410-3.

PMID:
8432128
4.

[Assessing the usefulness of erlotinib in patients with unknown or negative epidermal growth factor receptor mutation status].

Ema T, Kawano R, Enomoto Y.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1377-80. Japanese.

PMID:
24196074
5.

Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.

Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.

Lung Cancer. 2012 Aug;77(2):464-8. doi: 10.1016/j.lungcan.2012.04.013. Epub 2012 May 12. Review.

6.

New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.

Illiano A, Barletta E, De Marino V, Battiloro C, Barzelloni M, Scognamiglio F, Rossi N, Zampa G, De Bellis M, Gridelli C.

Anticancer Res. 2000 Sep-Oct;20(5C):3999-4003.

PMID:
11268491
8.

Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer.

Laohavinij S, Maoleekoonpairoj S, Cheirsilpa A, Maneechavakajorn J, Sirachainant E, Arpornvivat W, Jaisathaporn K, Ratanatharathorn V.

Lung Cancer. 1999 Dec;26(3):175-85.

PMID:
10598928
9.

Pulmonary resection for lung cancer in HIV-positive patients with low (<200 lymphocytes/mm(3)) CD4(+) count.

Massera F, Rocco G, Rossi G, Robustellini M, Pona CD, Meroni A, Rizzi A.

Lung Cancer. 2000 Aug;29(2):147-9.

PMID:
10963845
10.

Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.

Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.

Antivir Ther. 1997 Jul;2(3):175-83.

PMID:
11322272
11.

Giant cell lung carcinoma in a man with acquired immunodeficiency syndrome.

Kodama T, Miyazaki K, Satoh H, Hitomi S, Ohtsuka M.

Med Oncol. 2009;26(2):167-9. doi: 10.1007/s12032-008-9103-x. Epub 2008 Oct 21.

PMID:
18937080
12.

Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M.

Jancarikova D, Pesek M, Benesova L, Topolcan O, Holubec L Jr, Minarik M.

Anticancer Res. 2007 Jul-Aug;27(4A):1879-82.

13.

Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.

Kousignian I, Abgrall S, Grabar S, Mahamat A, Teicher E, Rouveix E, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Clin Infect Dis. 2008 Jan 15;46(2):296-304. doi: 10.1086/524753.

PMID:
18171266
14.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S.

J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11.

PMID:
19433683
16.

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.

Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.

Cancer. 2001 Dec 1;92(11):2902-10.

PMID:
11753965
17.

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M.

Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16.

PMID:
23332288
18.

Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.

Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.

Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6. doi: 10.1007/s00280-012-1910-2. Epub 2012 Jun 30.

PMID:
22752216
19.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
20.

Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.

Ren S, Li Y, Li W, Zhao Z, Jin C, Zhang D.

Respiration. 2012;84(5):431-5. doi: 10.1159/000339508. Epub 2012 Aug 9.

Supplemental Content

Support Center